![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Integrase Genotypic and Phenotypic Predictors of Antiviral Response to Dolutegravir (DTG) in Subjects With Resistance to Integrase Inhibitors (INIs)
|
|
|
Reported by Jules Levin
International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 4-8, 2013; Toronto, ON, Canada
CL Vavro,1 J Huang,2 MR Underwood,1 M Ait-Khaled,3 J Sievers,3 JM Yeo3
GlaxoSmithKline, 1Research Triangle Park, NC, USA; 2Toronto, ON, Canada; 3Stockley Park, London, UK
ResisWksp: Analysis and Characterization of treatment-Emergent Resistance in ART-Experienced, Integrase Inhibitor-Naïve Subjects With Dolutegravir (DTG) vs Raltegravir (RAL) in SAILING (ING111762) (06/09/13)
ResisWksp: Epidemiology of Dolutegravir (DTG) Resistance in ~700 RAL-Resistant Isolates (06/09/13)
![ResisWksp1.gif](../images/061113/061113-2/ResisWksp1.gif)
![ResisWksp2.gif](../images/061113/061113-2/ResisWksp2.gif)
![ResisWksp3.gif](../images/061113/061113-2/ResisWksp3.gif)
![ResisWksp4.gif](../images/061113/061113-2/ResisWksp4.gif)
![ResisWksp5.gif](../images/061113/061113-2/ResisWksp5.gif)
![ResisWksp6.gif](../images/061113/061113-2/ResisWksp6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|